131 related articles for article (PubMed ID: 12597347)
1. Second-line chemotherapy of epithelial ovarian cancer.
Markmon M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
[TBL] [Abstract][Full Text] [Related]
2. [Second-line chemotherapy and new drugs for ovarian carcinoma].
Priolo D; Antonelli G; Calì S; Colina P; Giuffrida D; Malaponte E; Mattina M; Parisi A; Sambataro D; Vitale F; Ferraù F
Clin Ter; 2001; 152(1):39-50. PubMed ID: 11382169
[TBL] [Abstract][Full Text] [Related]
3. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
4. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
5. Role of chemotherapy in the management of ovarian cancer.
Markman M
Expert Rev Anticancer Ther; 2002 Feb; 2(1):90-6. PubMed ID: 12113074
[TBL] [Abstract][Full Text] [Related]
6. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
7. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
Abou-Jawde RM; Oberoi SS
J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
[No Abstract] [Full Text] [Related]
8. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
[TBL] [Abstract][Full Text] [Related]
9. Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ
J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
[TBL] [Abstract][Full Text] [Related]
10. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
11. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
12. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Markman M; Kennedy A; Kim J
Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
[TBL] [Abstract][Full Text] [Related]
13. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Markman M; Markman J; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
J Clin Oncol; 2004 Aug; 22(15):3120-5. PubMed ID: 15284263
[TBL] [Abstract][Full Text] [Related]
14. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
15. Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP; Schilder RJ
Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Markman M
Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
18. Management of recurrent epithelial ovarian carcinoma.
Vasey PA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):269-77. PubMed ID: 16029291
[TBL] [Abstract][Full Text] [Related]
19. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
[TBL] [Abstract][Full Text] [Related]
20. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
